Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma by Lundblad, Lennart KA et al.
RESEARCH Open Access
Detrimental effects of albuterol on airway
responsiveness requires airway inflammation and
is independent of b-receptor affinity in murine
models of asthma
Lennart KA Lundblad
1*, Lisa M Rinaldi
1, Matthew E Poynter
1, Erik P Riesenfeld
1, Min Wu
1, Steven Aimi
1,
Leesa M Barone
2, Jason HT Bates
1, Charles G Irvin
1
Abstract
Background: Inhaled short acting b2-agonists (SABA), e.g. albuterol, are used for quick reversal of
bronchoconstriction in asthmatics. While SABA are not recommended for maintenance therapy, it is not
uncommon to find patients who frequently use SABA over a long period of time and there is a suspicion that long
term exposure to SABA could be detrimental to lung function. To test this hypothesis we studied the effect of
long-term inhaled albuterol stereoisomers on immediate allergic response (IAR) and airway hyperresponsiveness
(AHR) in mouse models of asthma.
Methods: Balb/C mice were sensitized and challenged with ovalbumin (OVA) and then we studied the IAR to
inhaled allergen and the AHR to inhaled methacholine. The mice were pretreated with nebulizations of either
racemic (RS)-albuterol or the single isomers (S)- and (R)-albuterol twice daily over 7 days prior to harvest.
Results: We found that all forms of albuterol produced a significant increase of IAR measured as respiratory
elastance. Similarly, we found that AHR was elevated by albuterol. At the same time a mouse strain that is
intrinsically hyperresponsive (A/J mouse) was not affected by the albuterol isomers nor was AHR induced by
epithelial disruption with Poly-L-lysine affected by albuterol.
Conclusions: We conclude that long term inhalation treatment with either isomer of albuterol is capable of
precipitating IAR and AHR in allergically inflamed airways but not in intrinsically hyperresponsive mice or
immunologically naïve mice. Because (S)-albuterol, which lacks affinity for the b2-receptor, did not differ from (R)-
albuterol, we speculate that isomer-independent properties of the albuterol molecule, other than b2-agonism, are
responsible for the effect on AHR.
Background
Inhaled short acting beta agonists (SABA) such as albuterol
are critical for quick reversal of acute bronchoconstriction
in asthmatics. While SABAs are not recommended for
maintenance therapy, it is not uncommon for patients to
frequently use SABA over an extended period of time and
it has been debated whether long term use of SABA is det-
rimental in asthma [1,2]. b2-agonists are primarily thought
to be bronchodilatory drugs acting via relaxation of airway
smooth muscle; however, there is also increasing evidence
that b2-agonists have other pharmacodynamic effects in
the lungs. Terbutaline and formoterol have been shown to
inhibit plasma extravasation in inflamed airways of guinea-
pigs and rats [3] and formoterol reduced histamine-
induced extravasation in humans [4]. Notwithstanding
these beneficial effects documented with b2-agonists, they
were almost exclusively obtained with racemic compounds
and b2-agonists now carry a “black box” warning in many
countries because of suspicion that they might worsen
asthma if used alone.
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racemic mixtures. While the diastereomer has tradition-
ally been considered to be largely inactive, there is accu-
mulating evidence suggesting that isomers without
affinity for the b2-receptor may indeed have pharmaco-
logical effects of their own [5,6]. In the case of albuterol,
the b2-active isomer is (R)-albuterol whereas (S)-albu-
terol has about 100 times less affinity than does (R)-
albuterol for the b2-receptor [7,8]. While there has been
a longstanding debate whether the pharmacodynamic
effects of diastereomers are of significance or not [9,10],
there is also a suspicion that long-term exposure to b2-
agonists could be detrimental to lung function [11]. We
recently showed that a long acting b2-agonist, salme-
terol, worsened respiratory mechanics in a model of
allergic asthma [12]. To test the hypothesis that albu-
terol increases airways hyperresponsiveness in inflamed
lungs, we studied the effect of long-term inhaled albu-
terol stereoisomers on respiratory reactivity in mouse
models of asthma, including immediate allergic response
(IAR) and allergen induced airways hyperresponsiveness
(AHR). Some of the data were previously presented in
preliminary form as abstracts at the 2008 and 2009
American Thoracic Society meetings [13,14] and the
2008 IDEA meeting [15].
Methods
Animals
Female mice (Balb/C, C57Bl/6 and A/J) were purchased
from Jackson Laboratories (Bar Harbor, ME). The mice
were housed in an AAALAC and USDA accredited ani-
mal facility at the University of Vermont fully equipped
for laboratory animal care. The study was approved by
the Institutional Animal Care and Use Committee at the
University of Vermont.
Allergen Sensitization
Female mice (Balb/C, 6 - 8 weeks of age) were sensitized
and challenged with chicken ovalbumin (OVA). Briefly,
on days 0 and 14, animals were injected (100:l, intraperi-
toneal (i.p.)) with OVA (20 μg) emulsified in 2.25 mg of
aluminum hydroxide/magnesium hydroxide.
Drug inhalation
(R)-, (S)- and (RS)-albuterol were dissolved in phosphate
buffered saline (PBS) vehicle and loaded into a Pari
nebulizer (6-8 ml). In another study, the Pari nebulizer
was reported to produce particles with a mass mean
aerodynamic diameter of 2.27 μm with a span of 2.04
μm, with the lung burden of Ova estimated at 10.4 μg
per administration [16]. The nebulizer was connected to
a multicompartment pie-shaped aerosol chamber where
the mice were exposed individually to the aerosol. Neb-
ulizations were delivered early in the morning and late
afternoon over 20 minutes. The doses were (R)- (2.5
mg/ml), (S)- (2.5 mg/ml), (RS)- (5 mg/ml) and control
PBS vehicle. The doses were chosen to be equipotent on
the b2-receptor based on the distribution of (S)- and
(R)- in racemic albuterol being 50% of each. The ani-
mals were treated for seven consecutive days with the
last nebulization 18 hours before readout.
Intra tracheal administration of Poly-L-lysine
T h em i c ew e r ea n e s t h e t i z e dw i t hs o d i u mp e n t o b a r b i t a l
(90 mg/kg, i.p.) and the trachea cannulated. The mice
were then placed supine at about 45°angle and a thin
catheter was forwarded through the cannula and 50 μl
of the PLL solution followed by about 0.5 ml of air was
forcefully injected into the airways. PLL was admini-
strated once 45 minutes before the assessment of AHR
with methacholine was started.
Assessment of the immediate allergic response (IAR)
The mice were immunized i.p. as described above and
on days 21-26 were exposed for 30 minutes to an OVA
aerosol once daily (1% (w/v) OVA in saline) generated
with an ultrasonic nebulizer. Control animals received a
saline-only aerosol. The mice were assessed for pulmon-
ary cellular infiltrates, histopathologies, and lung func-
tion on day 28. Following about ten minutes of regular
ventilation at a positive end-expiratory pressure (PEEP)
of 3 cmH2O, a standard lung volume history was estab-
lished by delivering two deep sighs to a pressure limit of
25 cmH2O where after two baseline measurements of
respiratory input impedance (Zrs) were obtained. Next,
lung mechanics was measured every 10 seconds for
1 minute immediately following inhalation of 5% OVA
aerosol (4 separate administrations, one minute chal-
lenges with 5 minutes washout in between each chal-
lenge) and then once every minute for 20 minutes. OVA
aerosol was delivered by temporarily channeling the
inspiratory flow from the ventilator through an ultraso-
nic nebulizer (Beetle Neb, Drive Intl. LLC, NY, particle
dimensions 1.5 to 5.7 μm) containing 5% OVA.
Assessment of airway hyperresponsiveness (AHR)
Balb/C mice were immunized i.p. as described above.
On days 21 - 23 they were exposed to 1% OVA aerosol
for 30 minutes. Control animals received saline-only
aerosol. On day 25 the mice were assessed for airway
hyperresponsiveness and pulmonary cellular infiltrates.
Lung mechanics was measured on day 25, 48 hr after
the last challenge with OVA. Following about ten min-
utes of regular ventilation at a positive end-expiratory
pressure (PEEP) of 3 cmH2O, a standard lung volume
history was established by delivering two deep sighs to a
pressure limit of 25 cmH2O. Next, two baseline mea-
surements of respiratory input impedance (Zrs)w e r e
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lized control PBS for 40 s, achieved by directing the
inspiratory flow from the ventilator through the aeroso-
lization chamber of an ultrasonic nebulizer (Beetle Neb,
Drive Intl. LLC, NY). Zrs was then measured every 10 s
for 3 min. Next, two deep sighs were delivered again
and two baseline recordings of Zrs were obtained fol-
lowed by methacholine inhalation. This was repeated for
three incremental doses of methacholine (3.125, 12.5,
50 mg/ml) with measurements as described for PBS.
Lung mechanics
The mice were anesthetized and cannulated as pre-
viously described [17,18]. The cannula was connected to
a flexiVent (SCIREQ Inc. Montreal, QC) and ventilated
at 200 breaths/minute. Zrs was determined from a two
second broadband perturbation in volume applied by
the flexiVent. The data was fitted with the constant
phase model [19]. At low frequencies the impedance of
the lung is extremely well described by the constant
phase model (Eq. 1):
Zrs(f)=Rn + i2πfI +
G − iH
(2πf)
α (1)
where Rn is the frequency independent Newtonian
resistance reflecting that of the conducting airways, I is
airway gas inertance, G characterizes tissue resistance, H
characterizes tissue stiffness, i is the imaginary unit, and
f is frequency in Hz [19,20].
Broncho alveolar lavage and cytology
At the end of the protocol the mice were euthanized
and the lungs lavaged with 1 ml of phosphate buffered
saline. Total cell counts were obtained and the lavage
was centrifuged and the supernatant was used for analy-
sis of cytokines (Bio-Plex
® M o u s eC y t o2 3 p l e x ) ,t o t a l
protein and IgG1. The cell pellet was then re-suspended
and cytospin slides prepared for cell differentials using
Hematoxylin - Eosin stain.
Histology
The lung was infused with formalin at 30 cm H2Oa n d
prepared for histology. Microscopic slides were prepared
and stained with Hematoxyl i n-E o s i nt ov i s u a l i z e
inflammatory cells and morphologic changes. Identifica-
tion of Clara cells was done by immunohistochemical
labeling using an antibody against Clara cell secretory
protein (CCSP) (Upstate cell signaling solutions) [21].
For fluorescent labeling of mucin, slides were stained
with periodic acid fluorescent Schiff stain (PAFS) to
visualize mucus producing cells using fluorescence
microscopy. PAFS staining allows for increased specifi-
city of mucin producing cells compared with traditional
periodic acid Schiff stain [21]. The slides were scored
from 0 (least staining) to 4 (most staining) by three
independent persons, masked to the identity of the
slides and the scores were then averaged. The scores
between persons were not significantly different (p >
0.05).
Protein analysis
The BALF was analyzed for total protein content using
the Bradford protein assay and measured in a plate
reader (Bio-Rad).
IgG1 analysis
The BALF was analyzed for total IgG1 content using
ELISA (Pharmingen).
Statistics
Statistical testing was done with one-way ANOVA with
Bonferroni post-hoc test. Statistics were calculated over
the entire time-course following each dose of allergen or
MCh. Histological scoring was tested with Kruskal-
Wallis test and Dunn’s multiple comparison post-hoc
test. A p < 0.05 was accepted as statistically significant
different.
Experimental design
The study was performed in two steps. The first part of
the study focused on elucidating the effects of albuterol
isomers on the IAR of the airways (Figure 1A) where as
the second part of the study was focused on studying
the effect of albuterol isomers on AHR. The latter part
of the study was performed in 5 different experiments;
naïve C57Bl6 and Balb/C represent mouse strains with
normal responsiveness, A/J mice are genetically hyperre-
sponsive, Balb/C mice challenged with Poly-L-lysine and
sensitized Balb/C representing allergically inflamed mice
that have hyperresponsive airways (Figure 1B).
In the experiment using PLL mice first underwent the
drug treatment and then on the day of experiment trea-
ted with PLL oropharyngeally and 45 minutes later
responsiveness to methacholine was assessed.
Results
Immediate Allergic Response (IAR)
Physiology
We first investigated the effects of allergen inhalation on
respiratory mechanics. Figure 2 shows the respiratory
mechanics derived from fitting the constant phase
model of the respiratory system to Zrs data in OVA
challenged mice. OVA inhalations produced small but
reproducible increases in Rn in all groups except the
group that received (R)-albuterol. There were, however,
no statistical differences between groups (p > 0.05).
After the fourth OVA exposure, lung mechanics were
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change significantly over the 20 minute period, with
either treatment, however, G and H increased signifi-
cantly over control (p < 0.001) in the mice treated with
(RS)-, (S)- and (R)-albuterol.
Cytology
After euthanasia the lungs were lavaged in situ with PBS
and the cellular inflammation was assessed. Figure 3
shows the result from counts of cells in BALF from
mice challenged with OVA. The cell number was
increased in all treated mice. The cytology was domi-
nated by eosinophils but neither treatment had any sig-
nificant effect on the relative cell differentials (% cell
numbers).
Cytokines
The sensitization and challenge protocol we use typically
produces a Th2 dominated cytokine profile; hence we
wanted to confirm this in this experiment. Figure 3
shows cytokine levels obtained from the Bio-Plex assay.
We found that KC and IL-12(p40) analyzed in bronch-
oalveolar lavage were significantly decreased by treat-
ment with (RS)-, (R)- and (S)- albuterol (p < 0.05). IL-5,
IL-4 and IL-13 were significantly elevated over saline
Figure 1 Timelines of the experiments. A)T om e a s u r et h e
immediate allergic airways response (IAR) Balb/C mice were
immunized with OVA + Alum i.p. on days 0 and 14. On days 21-26,
animals were exposed for 30 minutes to 1% aerosolized OVA;
controls received PBS aerosol. Four different groups of mice were
treated with nebulized albuterol, (R)- (2.5 mg/ml), (S)- (2.5 mg/ml),
(RS)- (5 mg/ml) or control PBS, twice daily for 20 minutes in the
morning and in the afternoon on days 21-27. Lung mechanics was
measured on day 28 following inhalation of 5% OVA aerosol. B) To
measure the effect of albuterol on allergen induced AHR, Balb/C
mice were immunized with OVA + Alum i.p. on days 0 and 14. On
days 21-23 animals were exposed for 30 minutes to 1% aerosolized
OVA; controls received PBS aerosol. The mice were treated with
nebulized albuterol, (R)- (2.5 mg/ml), (S)- (2.5 mg/ml), (RS)- (5 mg/
ml) or control PBS, twice daily for 20 minutes in the morning and in
the afternoon on days 18-24. AHR was assessed by measuring Zrs at
increasing doses of inhaled methacholine (MCh).
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Figure 2 Effect of albuterol on respiratory mechanics in mice
sensitized and challenged with OVA. Balb/C mice were
anesthetized and connected to a flexiVent and then received
inhalation challenges of aerosolized OVA. The OVA inhalation was
repeated 4 times and the respiratory impedance was measured
after each challenge as indicated by arrows and numbers on the X-
axis as follows: Following OVA inhalation at indicator 1, 2, 3 and 4
respiratory mechanics was measured every 10 seconds for 1 minute;
following OVA inhalation at indicator 5 mechanics was measured
once every minute for 20 minutes. Parameters from fitting the
constant phase model to input impedance data are shown. Rn is
Newtonian resistance of the conducting airways; H is lung elastance
and G is tissue resistance. Animals were treated with (RS)-, (R)- or
(S)- albuterol (n = 14, 13 and 15) twice daily for seven days with the
last administration 18 hours before experiment. PBS (n = 9) was
used as vehicle control. Both H and G were significantly elevated by
(RS)-, (R)- and (S)- albuterol compared with control PBS over the 30
- 60 minutes interval (*** p < 0.001). Changes in Rn were not
statistically significant (p > 0.05).
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Page 4 of 12Figure 3 Cell differentials, cytokine titers, plasma indicators from BALF and histology scores. Following euthanasia, lungs were lavaged
with 1 ml of PBS, and cells were counted, and cytospin slides were stained with H&E (n = 5 in each group). No statistically significant
differences were found between treatment groups (p > 0.05). Cytokine concentrations were measured from the BALF supernatant using Bio-
Plex
®. * p < 0.05, ** p < 0.01, (n = 10 in each group). Results of scoring of PAFS stained histological sections of lungs; no statistical difference
was found between groups. Results of scoring of CCSP staining; no statistical difference was found between groups (n = 5 in each group). Total
BALF protein was significantly increased in mice treated with (RS)-albuterol compared with (R)- and (S)-albuterol (* p < 0.05) whereas IgG1 in
BALF was not affected by either treatment (n = 10 - 18 in each group).
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with the expected Th2 profile.
Histology
Mucus expression has been shown to be linked to AHR
[22] but it is not known if mucus expression is increased
following an IAR or if it would be affected by albuterol. As
shown in Figure 3 we determined the expression of mucus
by scoring PAFS stained slides of lungs obtained from
mice that were treated with either isomers of albuterol or
control saline post OVA challenge. The staining of mucin
was not different between the groups. Similarly we found
that the immunomodulatory and anti-inflammatory CCSP
was not affected by albuterol treatment.
Protein and IgG1
It has been shown that various challenges to the airway
mucosa can induce plasma extravasation [23] and it has
been suggested that components of the extravasate can
contribute to AHR [24]. We used IgG1 and total protein
content of the BALF as indicators of plasma leakage.
Figure 3 shows the results from the protein and IgG1
analysis in BALF. The total protein content of the BALF
was significantly increased in (RS)-albuterol treated mice
compared with (R)- and (S)- treated, however, there was
no difference compared with the control group. IgG1
was measured as an indicator of plasma leakage. There
was, however, no difference in BALF IgG1 levels
between treatments suggesting that no significant exu-
dation took place.
Airways Hyperresponsiveness (AHR)
Physiology
AHR is a hallmark of allergically inflamed airways, thus
we next studied the effect of (RS)-, (S)- or (R)- albu-
terol treatment on AHR in allergically sensitized and
challenged mice. This was done measuring Zrs at
increasing doses of methacholine. Figure 4 shows the
respiratory mechanics dose-response to incremental
methacholine inhalations in allergic Balb/C mice.
Treatment with either (RS)-, (S)- or (R)-albuterol had
no significant effect on the increase in Rn or G.A l l
treatments did, however, significantly increase the
response in H, commensurate with increased lung stiff-
n e s sd u el i k e l yt oa i r w a yc l o s u r e[ 1 8 ] .T h i sf i n d i n g
then prompted us to investigate if albuterol would
affect the airways responsiveness of naïve mice. We
studied this in three different strains of mice pre-
viously shown to have different degrees of responsive-
ness to methacholine. Other studies have shown the
order of sensitivity to methacholine to be A/J > Balb/C
> C57Bl/6 [25-27], with A/J often considered to be
genetically hyperresponsive. We found that naïve mice
of all of these strains were unaffected by either (RS)-,
(S)- or (R)- albuterol treatment to a significant degree
(Figures 4 and 5).
Another predisposition for AHR could be epithelial
injury, as is frequently seen in asthma. The epithelial
lining of the airways is damaged by inflammatory pro-
cesses and it has been suggested that desquamation and
denudation of the epithelium are significant features of
asthma [28]. Although the causes of epithelial injury can
be multiple, one source that is likely to be important is
the release of cationic proteins from eosinophils. When
eosinophils degranulate they release major basic protein
(MBP), a cationic protein that may injure the epithelium
[29]. We have previously shown that PLL increase AHR
via epithelial disruption and that this manifests in the
conducting airways suggesting that access to the smooth
muscle was facilitated by PLL [30]. Thus, we wanted to
determine whether increasing the AHR with PLL would
be affected by albuterol. Figure 5 shows the respiratory
mechanics from Balb/C mice challenged oropharyngeally
with PLL. Neither pretreatment with (RS)-, (S)- or (R)-
albuterol had any effect on the methacholine dose-
response following PLL.
Discussion
We have performed a detailed assessment of the effects
of racemic albuterol as well as its separate isomers on
the respiratory phenotype. In particular we focused on
the effects of albuterol isomers on allergen and metha-
choline perturbed respiratory mechanics following an
extended period of pretreatment with inhaled albuterol.
We were interested to investigate if albuterol might
induce effects that would persist beyond termination of
administration, therefore the study was designed in such
a manner that drugs were delivered twice daily over
seven days and then stopped 18 hours before analysis.
With this approach, the drug had time to wash out and
we were studying only the sequelae of the treatment
a n dn o tt h ed i r e c te f f e c to ft h ed r u g ,s u c ha sb r o n c h i a l
relaxation. First, we studied whether albuterol affects
allergen induced responses in the lung. We found that
the IAR in terms of H and G were increased. With this
piece of information, we then speculated that AHR
might also be affected. Hence, we studied the effect of
albuterol on allergen-induced AHR and discovered that
AHR in terms of H was elevated by treatment with
(RS)-, (S)- and (R)- albuterol. Finally we tested whether
the AHR could be due to epithelial disruption or effects
on the smooth muscle and found that neither could
explain the increase in AHR caused by extended albu-
terol treatment.
We triggered the IAR by administering nebulized
OVA to allergic mice and then immediately started
tracking the respiratory mechanics. We expected the
OVA to trigger a constriction of airway smooth muscle
that would be seen as an increase in Rn.T h er e s p o n s e s
in Rn elicited by OVA were generally small, but
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although not to a statistically significant extent (Figure 2).
If we compare the amplitude of the responses in Rn fol-
lowing an OVA challenge with the response seen in lungs
challenged with methacholine in Figures 4 and 5, we con-
clude that the airway constriction elicited by inhaled aller-
gen is very small and probably does not carry much
biological significance in the airways of mice. The increase
in H and G following the allergen challenge, on the other
hand, were much more pronounced over time in the pre-
sence of (RS)-, (S)- or (R)- albuterol. These observations
illustrate that mice are capable of generating a smooth
muscle response in the conducting airways when exposed
to allergen, however, the muscle response was small and
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probably not the location in which most of the activity of
the allergen takes place. Instead, the allergen induced
effects in the lung periphery (H and G) were augmented
with (RS)-, (S)- or (R)- albuterol likely due to closure of
peripheral airways [18].
Inhalation of allergen is a common trigger of asthma
and instigates an immediate release of mediators from
mast cells that have the capacity to activate a number of
pathways that lead to lung inflammation and AHR [31].
Some of the mast cell mediators, e.g. histamine and ser-
otonin, have the capacity to stimulate smooth muscles
to contract, whereas other mediators are involved in the
cascade that leads to overt inflammation, including
recruitment of leucocytes, plasma leakage and eventually
AHR [32,33]. The immediate response to an allergen
challenge is usually manifest as a bronchoconstriction of
the conducting airways leading to a reduction of airflow
and shortness of breath [33]. Typically, this IAR can be
successfully treated with inhaled bronchodilators such as
albuterol. The notion that b-agonists can cause a decline
in lung function is neither new nor is it limited to
observations in animal models. It was noted in a year-
long study that asthmatic patients treated as needed
with racemic fenoterol resulted in more exacerbations, a
significant decline in baseline lung function, and an
increase in airway responsiveness to methacholine, but
did not alter bronchodilator responsiveness [34]. As
indicated by our results, one explanation to the deterior-
ating lung function in patients could be that the albu-
terol treatment increased the propensity for airway
closure following allergen challenge.
We next addressed the cause of airway closure exacer-
bated by prolonged albuterol treatment by exploring
two alternative hypotheses.T h ef i r s ti st h a ti n c r e a s e d
mucus production from the epithelial cells is promoted
by albuterol treatment. The second is that albuterol
treatment increases plasma leakage into the lung. We
studied the mucus producing epithelial cells in a semi-
quantitative manner and found that the score of PAFS
positive cells was not augmented by any treatment. We
then focused on quantification of extravasation in the
BALF and used IgG1 and total protein in BALF as indi-
cators of plasma extravasation. The increase in total
protein in the (RS)-albuterol treated mice was small but
significant compared with (R)- and (S)-albuterol treated
mice, suggesting that (R)- and (S)-albuterol, which
otherwise had no significant effect on plasma extravasa-
tion on their own, may have mild detrimental effects on
plasma extravasation when administered simultaneously
as a racemic mixture. IgG1 extravasation into the lung,
on the other hand, was not affected by albuterol. A
recent study from our group demonstrated that AHR
induced by acute acid aspiration correlates with BALF
protein, whereas this correlation was lost over time, pos-
sibly due to healing of the acid induced epithelial injury
[35]. The techniques we used to study extravasation
herein do not directly measure plasma leakage, hence,
we are unable to completely rule out the possibility that
plasma leakage did occur. Notwithstanding this uncer-
tainty, our data do not support plasma extravasation as
a mechanism for why the isomers of albuterol and the
racemic mixture produced similar degrees of airway
closure.
We performed an extensive analysis of BALF cyto-
kines one hour post allergen challenge. While the con-
centrations of most cytokines did not change and the
titers were generally low, we found that IL-4, IL-5 and
IL-13 were significantly increased in mice treated with
(RS)-albuterol. These cytokines are conventionally con-
sidered as Th2 cytokines and thought to promote the
asthma phenotype [36]. Chronic administration of var-
ious racemic b2-agonists have been shown to induce
increased production of pro-inflammatory IL-13 in Th2
cells from asthmatic patients in vitro, which was sug-
gested to be independent of the isomer of albuterol[37].
In this context, it is interesting to note that in our study
t h es i n g l ei s o m e r( R ) - a l b u t erol did not significantly
induce inflammatory cytokines. However, when (S)-albu-
terol was present in the form of (RS)-albuterol, the pic-
ture changed in the direction of more Th2 cytokines
being produced. The significant decreases in IL-12p40
in the BALF from mice receiving (RS)-albuterol may
partially explain the observed increases in Th2 cytokines
from these same mice, as IL-12p40 acts as a negative
regulator of IL-12p70 signaling [38], which itself func-
tions to promote Th1 responses that antagonize Th2.
The increase in Th2 cytokines did not seem to affect
respiratory mechanics, as we did not measure any differ-
ence between (RS)-albuterol and the pure isomers when
the mice were challenged with allergen. Studies in vitro
have shown that (S)-albuterol may activate mast cells
and enhance release of histamine and IL-4 [39], which
could adversely affect patients.
The total cell number present in lavageable airspaces
appeared increased in all treatment groups although not
statistically significant (Figure 3) and the cell differen-
tials revealed that the inflammation was dominated by
eosinophils.
A significant problem in asthma is the hyperrespon-
siveness to various inhaled stimuli [40,41]. Testing
patients for hyperresponsiveness helps in setting the
diagnosis of asthma. As it has been suggested that
extensive b2-agonist treatment might contribute to the
development of hyperresponsiveness, we designed
experiments to address this issue in vivo in different ani-
mal models. We found that pretreatment with either
compound had an effect on methacholine induced
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evidenced by a significant increase in H commensurate
with an increase in lung de-recruitment [18]. From
these data, we draw the conclusion that b-receptor inde-
pendent properties of albuterol appear to augment the
AHR in allergic mice. We also found that (S)-albuterol
did not affect H neither in a strain known to be geneti-
cally hyperresponsive (A/J (Figure 5) nor in normal
responsive animals (non-allergic Balb/C and C57Bl/6
(Figure 4, 5)). A/J mice exhibit AHR as an increase in
Rn, which in turn depends on the airway smooth muscle
having a higher shortening velocity in the A/J compared
to that of most other mouse strains [26,42]. Since AHR
was not affected by albuterol in A/J mice (Figure 5), this
suggests that the AHR increase in OVA sensitized mice
was probably not due to effects on the airway smooth
muscle. Thus, it appears that preexisting lung inflamma-
tion is necessary for albuterol to cause further negative
effects on the hyperresponsiveness of the respiratory
system. Since each of the isomers of albuterol, as well as
the racemic mixture, increased AHR, the mechanism
must be b-receptor independent.
When comparing the results obtained with IAR and
AHR we noticed a qualitative difference in that inhaled
OVA (Figure 2) generated an increase in both G and H,
whereas inhaled methacholine (Figure 4) produced only
an increase in H. We speculate that these differences are
explained by the different modes of action of methacho-
line and OVA. Methacholine stimulates airway smooth
muscle directly via muscarinic receptors, accounting for
the effect on Rn. Methacholine is also a secretagogue
with the capacity to trigger epithelial cells to expel mucus
[43] which might account for airway closure and the
increase in H. OVA, on the other hand, acts more indir-
ectly via intermediary resident and inflammatory leuko-
cytes (i.e. mast cells) [32] that conceivably could trigger
both mucus secretion and alterations in the visco-elastic
properties of the lung, thereby leading to a more complex
response including both G and H.
It is, of course, difficult to compare clinical asthma
with our mouse model particularly since we used a
long-term treatment protocol followed by a wash-out
period. While only a few clinical studies with (S)-albu-
terol have been performed the results have been mixed.
Two crossover trials failed to detect any increase in
AHR with a single dose of 100 μg (S)-albuterol [44,45],
whereas another study detected an increase in AHR,
albeit after a much higher single dose of (S)-albuterol,
(5 mg) [46]. Taken together, this might suggest that
either high doses or sustained treatment with albuterol
is needed to reveal any adverse effects on AHR.
We administered a model cationic protein, PLL, that
mimics MBP from eosinophils, which has been shown
to induce increased permeabilization of the epithelial
lining [47] with subsequent hyperresponsiveness to
inhaled methacholine, which in turn is probably due to
increased epithelial permeability primarily affecting the
conducting airways [30,48]. It has also been shown that
salmeterol prevents compromise of the airway epithelial
barrier when histamine-1 receptor or Protease Activated
Receptor-2 were activated in primary airway epithelium
[49]. We used PLL expecting that it would reveal effects
of the long-term treatment with albuterol isomers on
the smooth muscle. The hypothesis was that the smooth
muscle would normally be protected by an intact epithe-
lium disguising the effect of methacholine. We found
that PLL induced a robust response to methacholine
comparable to what has been shown before by our group
[50], however, pretreatment with albuterol did not affect
the response in any manner. Since albuterol did not
affect AHR in Poly-L-lysine treated mice (Figure 5) nor
in non-allergic mice (Figure 4 and 5), we conclude that
t h eA H Ri nO V Aa l l e r g i cm i c ew a sp r o b a b l yn o td u et o
changes in epithelial permeability.
Conclusion
In summary, we have determined the effects of chronic
(R)-, (S)- and (RS)-albuterol treatment on IAR and AHR
in mice. We found that all three drugs were equally
effective in causing peripheral airway closure following
an allergen challenge. The closure was not caused by
mucus production or by increased plasma extravasation.
All three compounds also increased the AHR to a simi-
lar degree. The expression of Th2 cytokines was some-
what elevated in mice treated with (RS)-albuterol;
however, this did not lead to a unique phenotype. The
effects of chronic albuterol treatment were not attributa-
ble to epithelial disruption because albuterol was not
affected by PLL instillation. In addition, the smooth
muscle did not seem to be involved because AHR in A/J
mice was not affected by albuterol treatment. These
observations also suggest that the airways are not nega-
tively affected by albuterol but rather that the periphery
of the lung is sensitive to adverse effects by albuterol.
Interestingly, our data demonstrate that pulmonary
inflammation seems to be a prerequisite for albuterol to
produce increased responses to either allergen or MCh
because naïve mice did not change their response fol-
lowing albuterol treatment. Finally, we are left with the
notion that the individual enantiomers and racemic
albuterol share the same ability to affect the lung pheno-
type whether induced by allergen inhalation or broncho
constriction with MCh and that this ability is not related
to the b2-receptor but is due to some other property of
the albuterol molecule that is unrelated to its steric
configuration.
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